{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:11:21Z","timestamp":1791252681037,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T00:00:00Z","timestamp":1278460800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00280-010-1377-y","type":"journal-article","created":{"date-parts":[[2010,7,6]],"date-time":"2010-07-06T09:39:44Z","timestamp":1278409184000},"page":"945-954","source":"Crossref","is-referenced-by-count":65,"title":["Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors"],"prefix":"10.1007","volume":"67","author":[{"given":"E. Claire","family":"Dees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert H.","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"von Mehren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Danaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Ecsedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Stringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Eton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Fingert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,7]]},"reference":[{"key":"1377_CR1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1128\/MCB.22.3.874-885.2002","volume":"22","author":"C Crosio","year":"2002","unstructured":"Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, Zhou H, Sen S, Allis CD, Sassone-Corsi P (2002) Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 22:874\u2013885","journal-title":"Mol Cell Biol"},{"key":"1377_CR2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0962-8924(99)01658-X","volume":"9","author":"JR Bischoff","year":"1999","unstructured":"Bischoff JR, Plowman GD (1999) The Aurora\/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 9:454\u2013459","journal-title":"Trends Cell Biol"},{"key":"1377_CR3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrm1245","volume":"4","author":"M Carmena","year":"2003","unstructured":"Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4:842\u2013854","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"Pt 21","key":"1377_CR4","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1242\/jcs.112.21.3591","volume":"112","author":"R Giet","year":"1999","unstructured":"Giet R, Prigent C (1999) Aurora\/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. J Cell Sci 112(Pt 21):3591\u20133601","journal-title":"J Cell Sci"},{"key":"1377_CR5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/35048096","volume":"2","author":"EA Nigg","year":"2001","unstructured":"Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2:21\u201332","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1377_CR6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/2496","volume":"20","author":"H Zhou","year":"1998","unstructured":"Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S (1998) Tumour amplified kinase STK15\/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20:189\u2013193","journal-title":"Nat Genet"},{"key":"1377_CR7","first-page":"4115","volume":"62","author":"TM Goepfert","year":"2002","unstructured":"Goepfert TM, Adigun YE, Zhong L, Gay J, Medina D, Brinkley WR (2002) Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res 62:4115\u20134122","journal-title":"Cancer Res"},{"key":"1377_CR8","doi-asserted-by":"crossref","first-page":"7148","DOI":"10.1038\/sj.onc.1209707","volume":"25","author":"X Wang","year":"2006","unstructured":"Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T, Deng CX (2006) Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25:7148\u20137158","journal-title":"Oncogene"},{"key":"1377_CR9","doi-asserted-by":"crossref","first-page":"8720","DOI":"10.1038\/sj.onc.1208153","volume":"23","author":"D Zhang","year":"2004","unstructured":"Zhang D, Hirota T, Marumoto T, Shimizu M, Kunitoku N, Sasayama T, Arima Y, Feng L, Suzuki M, Takeya M, Saya H (2004) Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene 23:8720\u20138730","journal-title":"Oncogene"},{"key":"1377_CR10","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-07-5268","volume":"14","author":"Y Nadler","year":"2008","unstructured":"Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y (2008) Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 14:4455\u20134462","journal-title":"Clin Cancer Res"},{"key":"1377_CR11","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1158\/1078-0432.CCR-07-0431","volume":"13","author":"CN Landen Jr","year":"2007","unstructured":"Landen CN Jr, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC, Gershenson DM, Brinkley WR, Sood AK (2007) Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 13:4098\u20134104","journal-title":"Clin Cancer Res"},{"key":"1377_CR12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1054\/bjoc.2000.1684","volume":"84","author":"C Sakakura","year":"2001","unstructured":"Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K, Shimomura K, Nakamura Y, Inazawa J, Abe T, Yamagishi H (2001) Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84:824\u2013831","journal-title":"Br J Cancer"},{"key":"1377_CR13","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1093\/emboj\/17.11.3052","volume":"17","author":"JR Bischoff","year":"1998","unstructured":"Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17:3052\u20133065","journal-title":"EMBO J"},{"key":"1377_CR14","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1158\/1078-0432.CCR-05-0805","volume":"12","author":"Y Yamamoto","year":"2006","unstructured":"Yamamoto Y, Matsuyama H, Kawauchi S, Furuya T, Liu XP, Ikemoto K, Oga A, Naito K, Sasaki K (2006) Biological characteristics in bladder cancer depend on the type of genetic instability. Clin Cancer Res 12:2752\u20132758","journal-title":"Clin Cancer Res"},{"key":"1377_CR15","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1158\/1078-0432.CCR-05-2339","volume":"12","author":"C Ginestier","year":"2006","unstructured":"Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide J, Xerri L, Viens P, Jacquemier J, Charafe-Jauffret E, Chaffanet M, Birnbaum D, Bertucci F (2006) Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 12:4533\u20134544","journal-title":"Clin Cancer Res"},{"key":"1377_CR16","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/94.17.1320","volume":"94","author":"S Sen","year":"2002","unstructured":"Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W, Czerniak B (2002) Amplification\/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94:1320\u20131329","journal-title":"J Natl Cancer Inst"},{"key":"1377_CR17","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-07-2179","volume":"14","author":"O Gautschi","year":"2008","unstructured":"Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res 14:1639\u20131648","journal-title":"Clin Cancer Res"},{"key":"1377_CR18","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1073\/pnas.0608798104","volume":"104","author":"MG Manfredi","year":"2007","unstructured":"Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 104:4106\u20134111","journal-title":"Proc Natl Acad Sci USA"},{"key":"1377_CR19","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1128\/MCB.02364-06","volume":"27","author":"K Hoar","year":"2007","unstructured":"Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, Ecsedy JA (2007) MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 27:4513\u20134525","journal-title":"Mol Cell Biol"},{"key":"1377_CR20","unstructured":"Huck J, Chakravarty A, Yu L, Zhang M, Burke K, Kim M-S, Stringer B, Sells T, Claiborne C, Manfredi M (2007) Preclinical PK\/PD\/efficacy relationship of MLN8054, a small molecule Aurora A kinase inhibitor 2007 (Abstract C191). AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, San Francisco, CA"},{"key":"1377_CR21","first-page":"73","volume":"70","author":"JM Collins","year":"1986","unstructured":"Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70:73\u201380","journal-title":"Cancer Treat Rep"},{"key":"1377_CR22","unstructured":"Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, December 12, 2003. Available online: http:\/\/ctep.cancer.gov\/reporting\/ctc.html"},{"issue":"12","key":"1377_CR23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1359-6349(08)72349-8","volume":"6","author":"Y Lee","year":"2008","unstructured":"Lee Y, Eton O, Pappas J, Chen S, Paton M, Dees EC, Jones S, Cohen RB, Cervantes A, Tabernero J (2008) Dosing strategies for MLN8054, a selective Aurora A kinase inhibitor, based on pharmacokinetic modeling and simulations. Eur J Cancer Suppl 6(12):130\u2013131","journal-title":"Eur J Cancer Suppl"},{"key":"1377_CR24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1377_CR25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nrc1502","volume":"4","author":"N Keen","year":"2004","unstructured":"Keen N, Taylor S (2004) Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4:927\u2013936","journal-title":"Nat Rev Cancer"},{"key":"1377_CR26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrc2049","volume":"7","author":"JR Jackson","year":"2007","unstructured":"Jackson JR, Patrick DR, Dar MM, Huang PS (2007) Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7:107\u2013117","journal-title":"Nat Rev Cancer"},{"key":"1377_CR27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/13543780902806392","volume":"18","author":"CH Cheung","year":"2009","unstructured":"Cheung CH, Coumar MS, Hsieh HP, Chang JY (2009) Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 18:379\u2013398","journal-title":"Expert Opin Investig Drugs"},{"issue":"15s","key":"1377_CR28","doi-asserted-by":"crossref","first-page":"Abstr 2565","DOI":"10.1200\/jco.2009.27.15_suppl.2565","volume":"27","author":"A Cervantes-Ruiperez","year":"2009","unstructured":"Cervantes-Ruiperez A, Elez ME, Rosell\u00f3 S, Macarulla T, Rodr\u00edguez-Braun E, Lee Y, Ecsedy J, Liu H, Fingert H, Tabernero J (2009) Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 27(15s):Abstr 2565","journal-title":"J Clin Oncol"},{"issue":"15S","key":"1377_CR29","doi-asserted-by":"crossref","first-page":"a2520","DOI":"10.1200\/jco.2008.26.15_suppl.2520","volume":"26","author":"RB Cohen","year":"2008","unstructured":"Cohen RB, Jones SF, von Mehren M, Cheng J, Spiegel DM, Laffranchi B, Mariani M, Spinelli R, Magazzu D, Burris HA III (2008) Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24\u00a0h infusion without\/with G-CSF in a 14-day cycle in patients with advanced solid tumors. J Clin Oncol 26(15S):a2520","journal-title":"J Clin Oncol"},{"issue":"15S","key":"1377_CR30","doi-asserted-by":"crossref","first-page":"a2517","DOI":"10.1200\/jco.2008.26.15_suppl.2517","volume":"26","author":"SF Jones","year":"2008","unstructured":"Jones SF, Burris HA III, Dumez H, Infante JR, Fowst C, Gerletti P, Xu H, Jakubczak J, Mellaerts N, Sch\u00f6ffski P (2008) Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: preliminary results. J Clin Oncol 26(15S):a2517","journal-title":"J Clin Oncol"},{"issue":"12","key":"1377_CR31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1359-6349(08)72214-6","volume":"6","author":"J Infante","year":"2008","unstructured":"Infante J, Dees EC, Cohen RB, Burris H, O\u2019Neil B, Murphy P, Lee Y, Pappas J, Ecsedy JA, Eton O (2008) Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States. Eur J Cancer Suppl 6(12):90\u201391","journal-title":"Eur J Cancer Suppl"},{"issue":"12","key":"1377_CR32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1359-6349(08)72219-5","volume":"6","author":"J Tabernero","year":"2008","unstructured":"Tabernero J, Cervantes A, Elez E, Macarulla T, Rosell\u00f3 S, Rodr\u00edguez-Braun E, Stringer B, Shinde V, Danaee H, Eton O (2008) MLN8237, an oral selective Aurora A kinase inhibitor: initial results of dose-finding pharmacokinetic-pharmacodynamic phase I study. Eur J Cancer Suppl 6(12):92","journal-title":"Eur J Cancer Suppl"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1377-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1377-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1377-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T21:01:12Z","timestamp":1635627672000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1377-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1377-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,7]]}}}